ACS 化学神经科学杂志特写：康百视。
ACS chemical neuroscience molecule spotlight on contrave.
机构信息
Department of Pharmaceutical Sciences, Lipscomb University College of Pharmacy , One University Park Drive, Nashville, Tennessee 37204, USA.
出版信息
ACS Chem Neurosci. 2011 Sep 21;2(9):484-6. doi: 10.1021/cn200076y.
Abstract
Contrave is an investigational fixed-dose combination drug of naltrexone and bupropion currently in Phase III clinical trials for the treatment of obesity. Orexigen Therapeutics, Inc. has demonstrated efficacy of their product and is currently addressing FDA safety concerns and deciding future actions.
摘要
康宝莱是一种正在进行 III 期临床试验的纳曲酮和安非他酮固定剂量组合药物，用于治疗肥胖症。Orexigen Therapeutics, Inc. 已经证明了其产品的疗效，目前正在解决 FDA 的安全问题，并决定未来的行动。
相似文献
1
ACS chemical neuroscience molecule spotlight on contrave.
ACS Chem Neurosci. 2011 Sep 21;2(9):484-6. doi: 10.1021/cn200076y.
2
Contrave--a combination of bupropion and naltrexone for weight loss.
Med Lett Drugs Ther. 2014 Nov 10;56(1455):112-4.
3
Naltrexone/bupropion: Contrave(R); naltrexone SR/bupropion SR.
Drugs R D. 2010;10(1):25-32. doi: 10.2165/11537710-000000000-00000.
4
ACS chemical neuroscience molecule spotlight on Qnexa.
ACS Chem Neurosci. 2011 Apr 20;2(4):183-4. doi: 10.1021/cn200023v.
5
A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
Obesity (Silver Spring). 2013 May;21(5):935-43. doi: 10.1002/oby.20309.
6
Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
Expert Opin Drug Saf. 2014 Jun;13(6):831-41. doi: 10.1517/14740338.2014.909405. Epub 2014 Apr 28.
7
Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity.
Expert Rev Clin Pharmacol. 2016;9(1):27-34. doi: 10.1586/17512433.2016.1100072. Epub 2015 Oct 29.
8
Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity.
Curr Opin Investig Drugs. 2009 Oct;10(10):1117-25.
9
Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes.
Future Cardiol. 2016 Mar;12(2):129-38. doi: 10.2217/fca.15.79. Epub 2015 Dec 18.
10
Naltrexone extended-release plus bupropion extended-release for treatment of obesity.
JAMA. 2015;313(12):1213-4. doi: 10.1001/jama.2015.1617.
引用本文的文献
1
Pharmacological Support for the Treatment of Obesity-Present and Future.
Healthcare (Basel). 2023 Feb 2;11(3):433. doi: 10.3390/healthcare11030433.
2
3
Metabolic vs. hedonic obesity: a conceptual distinction and its clinical implications.
Obes Rev. 2015 Mar;16(3):234-47. doi: 10.1111/obr.12246. Epub 2015 Jan 14.
4
Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date.
Drug Des Devel Ther. 2014 Sep 18;8:1419-27. doi: 10.2147/DDDT.S55587. eCollection 2014.
5
Phentermine and topiramate for the management of obesity: a review.
Drug Des Devel Ther. 2011 Apr 5;7:267-78. doi: 10.2147/DDDT.S31443. Print 2013.
本文引用的文献
1
Prevalence and trends in obesity among US adults, 1999-2008.
JAMA. 2010 Jan 20;303(3):235-41. doi: 10.1001/jama.2009.2014. Epub 2010 Jan 13.
2
Hypothalamic proopiomelanocortin neurons are glucose responsive and express K(ATP) channels.
Endocrinology. 2003 Apr;144(4):1331-40. doi: 10.1210/en.2002-221033.
3
Integration of NPY, AGRP, and melanocortin signals in the hypothalamic paraventricular nucleus: evidence of a cellular basis for the adipostat.
Neuron. 1999 Sep;24(1):155-63. doi: 10.1016/s0896-6273(00)80829-6.
4
Opioids hyperpolarize beta-endorphin neurons via mu-receptor activation of a potassium conductance.
Neuroendocrinology. 1990 Sep;52(3):268-75. doi: 10.1159/000125597.
Zotero 插件